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The protein S100A9 plays a key role in the control of inflammatory response. The C-terminus of the murine S100A9 protein
(mS100A9p) downregulates the spreading and phagocytic activity of adherent peritoneal cells. Murine peritoneal cells are
constituted bymacrophages and B-1 cells, and the latter exert an inhibitory effect onmacrophage functions by secreting interleukin-
(IL-) 10. Here, we investigated the influence of B-1 cells on the inhibitory effect evoked by mS100A9p on macrophages. mS100A9p
did not alter spreading and phagocytosis either by peritoneal macrophages obtained from mice deprived of B-1 cells or by bone
marrow-derived macrophages (BMDM𝜙). Nevertheless, when BMDM𝜙 were cocultivated by direct or indirect contact with B-1
cells treated with mS100A9p, the phagocytosis by BMDM𝜙 was decreased, showing that the effect of mS100A9p on macrophages
wasmodulated by B-1 cells and/or their secretory compounds. Furthermore, the inhibitory action of mS100A9p on phagocytosis by
adherent peritoneal cells was abolished in cells obtained from IL-10 knockoutmice. Taken together, the results show thatmS100A9p
has no direct inhibitory effect onmacrophages; however,mS100A9pmodulates B-1 cells, which in turn downregulatesmacrophages,
at least in part, via IL-10. These data contribute to the characterization of S100A9 functions involving B-1 cells in the regulation of
the inflammatory process.
1. Introduction
Phagocytes that express S100A8 and S100A9 proteins belong
to the first group of cells that infiltrate in inflammatory
sites and play a pivotal role in innate immune responses
[1, 2]. These proteins have attracted a special interest due to
their high cytosolic concentration in phagocytes and their
high intracellular calcium-binding capacity [3, 4]. Increased
plasma levels of S100A8/A9 have been found in patients
suffering from a number of inflammatory disorders, includ-
ing rheumatoid arthritis, inflammatory bowel disease, cystic
fibrosis, psoriasis, diabetes, systemic lupus erythematosus,
multiple sclerosis, and atherosclerosis, making this complex
a very useful biomarker of inflammatory diseases [5–8].
Extracellular S100A9 induces neutrophil chemotaxis and
adhesion [9–11], macrophage chemotaxis [12], degranula-
tion, and activation of neutrophils [13–15] and enhances
proinflammatory cytokine production by macrophages and
peripheral bloodmononuclear cells [16, 17]. S100A9 regulates
myeloid cell function by binding to Toll-like receptors- (TLR-
) 4 [13] and the receptor for advanced glycation end products
(RAGE) [18] and by modulating microtubule reorganiza-
tion during transendothelial migration [19], resulting in
proinflammatory effects. However, S100A9 expression also
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has anti-inflammatory effects, by deactivation of activated
peritoneal macrophages [20] and suppression of macrophage
activation following phagocytosis of apoptotic neutrophils
[21]. Our group has previously demonstrated that human
S100A9 and the synthetic peptide corresponding to the C-
terminal portion of the murine S100A9 protein (mS100A9p)
have antinociceptive activity in inflammatory pain models
[22–26]. Further, we showed that mS100A9p inhibits the
spreading and phagocytic activity of adherent peritoneal
cells stimulated or not with proteinase-activated receptor-1
[27, 28]. Thus, S100A9 has both proinflammatory and anti-
inflammatory activities, emphasizing the need to further
study its dual roles.
The peritoneal cavity is a unique compartment within
which a variety of immune cells reside, such as different
macrophages subsets [29] and B-1 cells [30]. B-1 cells rep-
resent the main B lymphocyte population in the peritoneal
and pleural cavities of mice [30]. B-1 cells express high levels
of IgM, low levels of IgD, and CD11b on their cell surface
and can be subdivided into B-1a (CD5+) and B-1b (CD5−)
cells, which develop from distinct progenitor cells [31, 32].
B-1b cells proliferate spontaneously in stationary cultures of
adherent mouse peritoneal cells and differentiate into a novel
type of mononuclear phagocytes [33]. B-1a cells are able to
differentiate into phagocytes when cocultivated with fibrob-
lasts [34]. Furthermore, B-1b cells leave peritoneal cavity and
migrate to inflammatory sites, where they are transformed
into a novel type of mononuclear phagocytes, which perform
the functions of adhesion, spreading and phagocytosis [33].
The egress from the peritoneal cavity occurs by direct signals
through Toll-like receptors, resulting in downregulation of
integrins and CD9 expression on B-1 cells, which are essential
for theirmobilization and participation in immune responses
[35].
B-1 cells can also influence the inflammatory milieu once
they are pivotal for giant cell formation [36], wound-healing
process via IL-10 [37], and inhibition of macrophage activi-
ties, also mediated by IL-10 [38]. Additionally, data support
the hypothesis that B-1 cells downregulate the macrophage
inflammatory response to eliminate parasites [39], exert a
tolerogenic function in a model of allergic reaction [40], and
modulate the innate immune system in the early phase of
endotoxemia [41, 42].
Considering that peritoneal cavity is constituted by
macrophages and B-1 cells, which have phagocytic activ-
ity, and that mS100A9p inhibits the activities of adher-
ent peritoneal cells, the aim of the present study was to
investigate whether the inhibitory effect induced by the C-
terminus of S100A9 protein is dependent on B-1 cells and/or
macrophages.
2. Material and Methods
2.1. Animals. Male BALB/c and BALB/xidmice (18–22 g) and
C57BL/6 and C57BL/6 IL-10 knockout (KO) mice (25–30 g)
were provided by Institutional Animal Facilities of Federal
University of Sa˜o Paulo (CEDEME). Male Swiss mice (18–
22 g)were provided by theCentral AnimalHouse of Butantan
Institute. Five animals were housed per cage, with wood
shaving, at a constant ambient room with controlled temper-
ature (22∘C ± 2∘C) and light/dark cycle (12/12 hours), with
free access to water and mice chow pellets, at least two days
before the experiments. Experimental proceedings were in
accordance with the guidelines for animal experimentation,
and the practices were approved by the Institutional Animal
Care Committee at the Butantan Institute (CEUAIB, protocol
number 072/2002).
2.2. Synthesis and Treatments with Peptide of S100A9.
The peptide H-E-K-L-H-E-N-N-P-R-G-H-G-H-S-H-G-K-G
(H92-G110; MW 2128.55Da), which is identical to the C-
terminus of mS100A9p, was synthesized based on a previ-
ously reported sequence [43]. This peptide was synthesized
in solid phase by FMOC technique.The characterization and
purification of the peptide were made by HPLC, and its mass
was evaluated by MALDI-TOF spectrometry. The peptide
was diluted in DMSO solution (15%) in Milli-Q water and
stored at −20∘C until the experiments. The peptide was used
in the concentrations of 0.59, 1.17, and 2.35 𝜇M(0.12, 0.25, and
0.5 𝜇g, resp.), based on previously published results [27].
2.3. Peritoneal Cell Preparation. BALB/c, BALB/xid,
C57BL/6, and C57BL/6 IL-10 KO mice were euthanized in a
CO
2
chamber and their peritoneal cavity was washed with
5mL of cold phosphate-buffered saline (PBS), pH 7.4. After
a gentle massage of the abdominal wall, the peritoneal fluid,
containing resident cells, was collected. Cell viability was
assessed by the Trypan blue exclusion test (>95%). Total
peritoneal cells were counted in a Neubauer’s chamber, and
differential counts were carried out in smears stained with
a panchromatic dye [44]. For all measurements, samples
of individual animals were used. The assays were always
performed in duplicates.
2.4. Bone Marrow-Derived Macrophages Culture (BMDM𝜙).
Bone marrow cells—freshly isolated from femora and tibia
of Swiss mice, euthanized in a CO
2
chamber—were cultured
on culture dishes for 7 days in RPMI-1640 medium (Sigma,
St. Louis, MO) supplemented with 20% heat-inactivated
fetal bovine serum and 30% L929 cell-conditioned medium
(LCCM) and used as a source of colony-stimulating factor-1
[45]. Differentiated macrophages were dispensed into dishes
by incubation with PBS supplemented with 2.5mM EDTA
for 15min. Supernatant was removed by centrifugation
(1.500 rpm/5min), and the cell pellet was resuspended with
RPMI medium. Cell viability was evaluated using the Trypan
blue dye exclusion method. mS100A9p was incubated for
1 h with adherent macrophages (1 × 105 cells/mL) during cell
spreading. Phospholipase A
2
(PLA
2
), isolated from Crotalus
durissus terrificus venom, which inhibits macrophage spread-
ing and phagocytosis [46], was incubated in the concentra-
tions of 0.85, 1.78, and 3.57 𝜇M (0.12, 0.25, and 0.5 𝜇g/mL,
resp.) for 1 h with BMDM𝜙 and used as a positive control to
ensure macrophage functionality.
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2.5. B-1 Cell Culture. B-1 cells were obtained as previously
described [33, 38]. Briefly, peritoneal cells were collected from
the abdominal cavity of Swiss mice by repeated lavage with
2mL of RPMI-1640 medium. Cell viability was evaluated
using the Trypan blue dye exclusion method. Cells (2 ×
105/mL) were dispensed on round glass coverslips (13mm) in
24-well plates (Costar, Tokyo, Japan) and cultures incubated
at 37∘C in 5% CO
2
for 40min; after incubation, nonadherent
cells were discarded. Adherent monolayers were rinsed with
RPMI, and subsequently R-10 medium (RPMI-1640 con-
taining 10% heat-inactivated fetal bovine serum) was added.
Cultures were then maintained at 37∘C in 5% CO
2
for 5 days,
without changing the medium, and at that time floating B-
1 cells were in large numbers. Nonadherent B-1 cells were
collected and submitted to cell function assays. mS100A9p
was incubated for 24 h with adherent B-1 cells, during cell
spreading.
2.6. Coculture of BMDM𝜙 and B-1 Cells. BMDM𝜙 (1 × 105
cells) were dispensed on round glass coverslips in 24-well
plates for 15min. After this period, B-1 cells (1× 105 cells) were
added directly over adherent macrophages. In another assay,
B-1 cells were added to the upper compartments of transwell
chambers (Costar). In both assays, in either the absence or
presence of transwell chambers, mS100A9p was incubated
concomitantly with B-1 cells for 1 h.
2.7. Spreading Assay. The spreading ability of peritoneal cells
obtained from BALB/c and BALB/xid mice, BMDM𝜙, or
B-1 cells was estimated according to a previously described
method [47]. Briefly, 100 𝜇L of cell suspensions in PBS
(1 × 105 cells) was placed onto glass coverslips and left to
adhere for 15min at room temperature. For B-1 cells, the
adherence was for 3 h. Coverslips were washed with PBS and
incubated in RPMImedium at 37∘C for 1 h, in the presence of
mS100A9p, during cell spreading. For B-1 cells, R-10 medium
was used for 24 h, incubated with mS100A9p. Cells were
fixed in a 2.5% glutaraldehyde solution and the index of cell
spreadingwas determined by phase contrastmicroscopy.This
index was defined as percentage of spread cells in 100 cells
counted. Spread cells were defined as adherent cells which
changed their rounded shape to a flattened shape, showing
a lower refractilebody and a higher diameter compared to
unspread cells [47].
2.8. Phagocytic Activity. Coverslips containing adherent and
spread cells of the peritoneal cavity of BALB/c, BALB/xid,
C57BL/6, and C57BL/6 IL-10 KO mice or BMDM𝜙 or B-1
cells were incubated with 1mL of RPMI medium containing
nonopsonized Candida albicans in an atmosphere contain-
ing 5% CO
2
for 1 h at 37∘C. The percentage of cells that
phagocytosed more than three particles was determined in
smears stained with a panchromatic dye [44], by examination
under light microscopy. Candida albicans (ATCC Y-537) was
cultured in 8%Sabouraud’s dextrose broth (Microbiology and
Mycology Laboratories, Department of Clinical Analyses,
College of Pharmaceutics Science, University of Sa˜o Paulo)
at 30∘C, for one day. Fungi were suspended in 3mL of
Dulbecco’s PBS for determining Candida albicans count in
Neubauer’s chamber, and then the particles were suspended
in RPMI medium for the phagocytosis assay. Candida albi-
cans viability was determined by exclusion of 0.01% methy-
lene blue (>98%). The particle count was approximately 1 ×
106 per coverslip.
2.9. Statistical Analysis. Results are expressed as means ±
standard deviation (SD). Comparisons between experimental
and control groupswere initially tested by analysis of variance
(ANOVA). The alpha level (significance level related to the
probability of rejecting a true hypothesis) was set at 𝑃 ≤ 0.05.
Significant differenceswere then compared usingTukey’s test.
3. Results
3.1. mS100A9p Did Not Alter the Spreading and the Phagocytic
Activity of Macrophages Obtained from BALB/xid Mice. In
order to evaluate the involvement of B-1 cells in mS100A9p-
induced inhibitory effect on macrophage spreading, we used
peritoneal cells obtained from BALB/xid mice, which are
deficient in B-1 cells [48]. For comparison, peritoneal cells
obtained from isogenic BALB/c mice were used. mS100A9p
downregulated spreading of peritoneal cells obtained from
BALB/c mice in the concentrations of 1.17 and 2.35 𝜇M (23
and 19% of inhibition, resp.), when compared with control
cells, incubated only with culture medium (Figure 1(a)). On
the other hand, mS100A9p, in both concentrations, did not
change spreading of peritoneal cells obtained from BALB/xid
mice (Figure 1(a)). In relation to the phagocytic activity of
Candida albicans particles, mS100A9p did not change the
phagocytosis by peritoneal cells obtained from BALB/xid
mice either (Figure 1(b)). mS100A9p inhibited the phagocy-
tosis by peritoneal cells obtained from BALB/c mice, in the
concentrations of 1.17 and 2.35𝜇M (44 and 28% of inhibition,
resp.) (Figure 1(b)).
3.2. mS100A9p Did Not Change the Spreading and the
Phagocytic Activity of BMDM𝜙. To confirm that mS100A9p
was unable to downregulate macrophage functions in the
absence of B-1 cells, mS100A9p was incubated with BMDM𝜙
during the spreading assay. mS100A9p, in concentrations
of 0.59, 1.17, and 2.35 𝜇M, did not alter BMDM𝜙 spread-
ing (Figure 2(a)). PLA
2
, the positive control of inhibition
of macrophage spreading and phagocytosis, downregulated
spreading of BMDM𝜙 (20% to 0.85 𝜇M, 24% to 1.78 𝜇M, and
24% to 3.57 𝜇M) (Figure 2(a)). Different concentrations of
mS100A9p incubated for 1 h with BMDM𝜙 during spreading
did not downregulate phagocytosis of Candida albicans
particles (Figure 2(b)). On the other hand, PLA
2
inhibited
phagocytosis by BMDM𝜙 in all concentrations used (32% to
0.85 𝜇M, 41% to 1.78𝜇M, and 44% to 3.57 𝜇M) (Figure 2(b)).
3.3. mS100A9p Downregulated Phagocytosis by BMDM𝜙
Cocultivated with B-1 Cells. In an attempt to evaluate if the
presence of B-1 cells was primordial to mS100A9p-induced
inhibition of macrophage spreading and phagocytosis, we
investigated the effect of mS100A9p on BMDM𝜙 cocultivated
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Figure 1: Spreading and phagocytosis assays by peritoneal cells obtained from BALB/c and BALB/xid mice after incubation with mS100A9p.
(a) Peritoneal cells were adhered to coverslips (1 × 105 cells/well) and incubated with mS100A9p (1.17 or 2.35𝜇M in RPMI-1640 medium), for
1 h at 37∘C in 5% CO
2
. Control adherent cells were incubated only with culture medium. (b) After spreading, cells were incubated with 1 ×
106 Candida albicans particles for 1 h. Results are expressed as means ± SD, using six animals per group. ∗𝑃 ≤ 0.05, when compared to the
respective control group (RPMI).
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Figure 2: Spreading and phagocytosis assays by bonemarrow-derivedmacrophages (BMDM𝜙) after incubationwithmS100A9p. (a) BMDM𝜙
adhered to coverslips (1 × 105 cells/well) were incubated with mS100A9p (0.59; 1.17; or 2.35 𝜇M in RPMI-1640 medium), for 1 h at 37∘C in 5%
CO
2
. Phospholipase A
2
(PLA
2
: 0.85; 1.78; 3.57 𝜇M), in the same conditions of peptide, was used as positive control. BMDM𝜙 controls were
incubated only with culture medium. (b) After spreading, BMDM𝜙 were incubated with 1 × 106 Candida albicans particles for 1 h. Results are
expressed as means ± SD, using five samples per group. ∗𝑃 ≤ 0.05, when compared to the control group (RPMI).
directly with B-1 cells. In the presence of the B-1 cells, phago-
cytosis of Candida albicans particles by BMDM𝜙 was inhib-
ited 28, 31, and 28%, which corresponded to concentrations of
0.59, 1.17, and 2.35 𝜇M mS100A9p, respectively (Figure 3(a)).
To verify whether the contact between these two cell types
was necessary to the inhibitory effect of mS100A9p, cocul-
tures of BMDM𝜙 and B-1, in the presence of mS100A9p,
were performed using transwell chambers. The absence of
direct contact between BMDM𝜙 and B-1 cells maintained
the downregulation of the macrophage phagocytic activity in
response to mS100A9p. The fall in phagocytosis was 25, 27,
and 23%, corresponding to concentrations of 0.59, 1.17, and
2.35 𝜇MmS100A9p, respectively (Figure 3(b)).
3.4. mS100A9p Inhibited Spreading and Phagocytosis by B-
1 Cells. Considering the inhibitory effect of mS100A9p in
the coculture of BMDM𝜙 and B-1, we evaluated whether the
peptide also exerted a direct action on B-1 cells. mS100A9p
induced a statistically significant reduction in spreading of B-
1 cells in the concentrations of 0.59 and 1.17 𝜇M (21 and 26%
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Figure 3: Phagocytosis assays by bone marrow-derived macrophages (BMDM𝜙), cocultivated with B-1 cells, treated with mS100A9p.
BMDM𝜙 adhered to coverslips (1 × 105 cells/well) were incubated in the presence of B-1 cells (1 × 105 cells/well) concomitant with mS100A9p
(0.59; 1.17; or 2.35 𝜇M in RPMI-1640 medium), for 1 h at 37∘C in 5% CO
2
. Coculture assays were evaluated with (a) or without (b) direct
contact of these two cell populations, using transwell chambers. Experimental controls were cocultures of BMDM𝜙 and B-1 cells incubated
only with culture medium. After 1 h, both cocultures were incubated with 1 × 106 Candida albicans particles for 1 h. Results are expressed as
means ± SD, using five samples per group. ∗𝑃 ≤ 0.05, when compared to the control group (RPMI).
of inhibition, resp.) (Figure 4(a)). In addition, mS100A9p
inhibited phagocytosis by B-1 cells, at the concentrations of
0.59, 1.17, and 2.25 𝜇M (34, 45, and 36%, resp.) (Figure 4(b)).
3.5. mS100A9p Did Not Alter Phagocytosis by Adherent Peri-
toneal Cells Obtained from IL-10 KO Mice. Since B-1 cells
secrete IL-10 [49], which inhibits murinemacrophage phago-
cytosis in vitro [38], we evaluated the involvement of IL-10
in mS100A9p-induced inhibitory effect on phagocytosis by
peritoneal cells obtained from IL-10 KOmice. Peritoneal cells
obtained from wild-type mice (C57BL/6) were used as con-
trol. mS100A9p downregulated phagocytosis by peritoneal
cells obtained from wild-type C57BL/6, in the concentration
of 2.35 𝜇M (25% of inhibition), when compared with control
cells incubated only with culture medium (Figure 5). The
peptide, in both concentrations (1.17 and 2.35 𝜇M), did not
modify phagocytosis by peritoneal cells from C57BL/6 IL-10
KO mice, when compared with control cells (Figure 5).
4. Discussion
S100A8/A9 are important proteins expressed by phago-
cytes during the inflammatory response [5]. The expres-
sion of these proteins is restricted to cells of the mono-
cytic/granulocytic lineage, but under certain conditions they
may also be expressed by keratinocytes [50, 51]. It was also
demonstrated that newly arrived inflammatorymacrophages,
but not the resident ones, express S100A8/A9 at inflamma-
tory sites for a short time [50, 52]. Both proinflammatory
and anti-inflammatory functions have been reported for
S100A8/A9, which may depend on several factors, including
their concentration, receptors involved in their recognition,
their posttranslational modifications, cell types studied, and
mediators of the local milieu [53, 54]. Previous studies of
our group demonstrated an inhibitory effect of either S100A9
or its C-terminal portion on an inflammatory nociception
model [22, 24, 26], suggesting that mS100A9p induces a
similar effect to that evoked by the complete protein. This
evidence supports the hypothesis that this peptide has a
crucial role in inflammatory events. In addition, mS100A9p
downregulated the spreading and phagocytosis by adherent
peritoneal cells in vivo and ex vivo [27, 28]. Considering the
inhibitory effect of mS100A9p on the activities of peritoneal
cells and that B-1 cells represent the main B cell population
in normal peritoneal cavity of mice [55], in this study it
was investigated whether the inhibitory effect induced by
C-terminus of S100A9 protein is related to an action on
macrophages and/or B-1.
Initially, we investigated the effect of mS100A9p on
spreading and phagocytosis by peritoneal cells from
BALB/xid mice, which are deficient in B-1 cells [48]. Our
data showed that mS100A9p did not inhibit the functions of
cells obtained from BALB/xid mice, suggesting an important
role of B-1 cells in mS100A9p-induced inhibitory effect on
adherent peritoneal cells.These data were supported by other
studies showing that absence of B-1 cells in BALB/xid mice
interfered with the inflammatory response, including the
activity and proliferation of peritoneal macrophages [38, 42],
control of infection [39, 56], and wound-healing process
[37].
To verify that mS100A9p did not act directly on
macrophage activity, the effect of mS100A9p on the func-
tional response of BMDM𝜙 was evaluated. Once mS100A9p
did not alter the spreading and phagocytosis of BMDM𝜙,
these data confirm that mS100A9p did not have a direct
action on macrophages. PLA
2
, used as a positive control,
inhibited spreading and phagocytosis by macrophages, as
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Figure 4: Spreading and phagocytosis assays by B-1 cells after incubation with mS100A9p. (a) B-1 cells, isolated by stationary culture of
peritoneal cells obtained from Swiss mice, were adhered per 3 h to coverslips (1 × 105 cells/well) and incubated with mS100A9p (0.59; 1.17;
or 2.35 𝜇M in R-10, RPMI-1640 medium containing 10% of heat-inactivated fetal bovine serum, R-10), for 24 h at 37∘C in 5% CO
2
. Control
adherent cells were incubated only with R-10. (b) After spreading, cells were incubated with 1 × 106 Candida albicans particles for 1 h. Results
are expressed as means ± SD, using six animals per group. ∗𝑃 ≤ 0.05, when compared to the control group (R-10).
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Figure 5: Phagocytic activity by peritoneal cells obtained from C57BL/6 wild-type (WT) and C57BL/6 IL-10 KO (IL-10 KO) mice after
incubation with mS100A9p. Peritoneal cells obtained were adhered to coverslips (1 × 105 cells/well) and incubated with mS100A9p (1.17 or
2.35 𝜇M in RPMI-1640 medium) for 1 h at 37∘C in 5% CO
2
. Control adherent cells were incubated only with culture medium. After this time,
cells were incubated with 1 × 106 Candida albicans particles for 1 h. Results are expressed as means ± SD, using six animals per group. ∗𝑃 ≤
0.05, when compared to the control group (RPMI).
described elsewhere [46]. These results demonstrated that
macrophages used in our assays were functioning normally.
Despite the findings obtained here, suggesting that the
inhibitory effect of mS100A9p is not due to a direct action
on macrophages, it has been showed that mS100A9p down-
regulates the phagocytic activity of apoptotic neutrophils by
macrophages [21]. Nevertheless, isolated macrophages have
not been used, and the mS100A9p effect was observed on
adherent peritoneal cells, which comprise macrophages and
B-1 cells. This fact could explain the discrepancy between the
results presented here and those reported by De Lorenzo et
al. [21].
Using coculture assays, it is well established that the
function of macrophages is largely regulated by intercel-
lular communication, which influences the development
and maintenance of the inflammatory response [57, 58].
Thus, by coculturing B-1 cells with macrophages obtained
from BALB/xid mice, IL-10 secreted by B-1 cells has been
demonstrated to modulate murine macrophage phagocytosis
[38]. Considering these data, it was investigated whether B-
1 cells treated with mS100A9p could modulate macrophage
phagocytosis. In addition, in an attempt to show whether the
effect of mS100A9p depended on a direct contact between B-
1 cells and macrophages, the coculture of these two cell types
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was performed in the absence or presence of transwell inserts.
Once a downregulatory effect of mS100A9p was observed
in both assays, we can suggest that the inhibitory effect of
mS100A9p on the adherent peritoneal cells, as previously
observed [27], is mediated by B-1 cells. These results also
showed that the direct contact between macrophages and B-1
cells is not essential to mS100A9p activity but is related to the
secretory activity of B-1 cells.
Considering that B-1 cells differentiate into a macro-
phage-like cells, exhibiting the ability to phagocytose either
in vitro or in vivo [33, 59], we decided to evaluate whether
mS100A9p had an effect on B-1 cell functions. The data
presented here show that mS100A9p downregulated the
spreading and phagocytosis by B-1 cells, suggesting that the
C-terminus of S100A9 not only modulates the action of
B-1 cells, which in turn inhibits the phagocytic activity of
macrophages, but also has a direct effect on B-1 cells, probably
by a communication via soluble autocrine and paracrine
signals. Also, we did not observe a concentration-dependent
effect of mS100A9p on spreading and phagocytosis assays
carried out.
Many factors have a regulatory role in macrophage activ-
ity, acting as key orchestrators of the inflammatory response.
In this sense, IL-10 has been found to downregulate a number
of different macrophage functions, including cytokine pro-
duction and the respiratory burst [60, 61], acting thereby as
an important negative regulator of cell-mediated immunity
[62]. Peritoneal B-1 cells are the major producers of IL-10
and they use it to regulate their own development and/or
the function of other immunocompetent cells [49, 63]. As
mentioned earlier, IL-10 secreted by B-1 cells downregulates
the phagocytic activity of macrophages [38] and modulates
the kinetics of wound-healing process [37]. Further, B-1 cells
from IL-10 KO mice were not able to inhibit macrophage
functions [38].
To investigate the IL-10 participation in mS100A9p-
induced inhibitory effect, we evaluated whether mS100A9p
altered the phagocytic activity of peritoneal cells obtained
from IL-10 KO mice. Considering that mS100A9p did not
change the activity of these cells, it is plausible to suggest
that mS100A9p induces the secretion of IL-10 by B-1 cells and
consequently inhibits its own functions and the activities of
peritoneal macrophages. In this regard, it was demonstrated,
in vitro and in vivo, that B-1 cells induce macrophage
polarization to an M2-like phenotype, which is anti-
inflammatory and immunosuppressive in nature, evidenc-
ing that IL-10 is crucial to modulate macrophage function
[64].
The mechanism by which mS100A9p regulates IL-10
secretion by B-1 cells is not known. However, both B-1
cell activation and IL-10 release are regulated by TLR-4
[65–67], and S100A9 protein acts as an endogenous TLR-
4 ligand, regulating thereby myeloid cell function [13, 68,
69]. In this sense, it is plausible to hypothesize that the C-
terminus of S100A9 stimulates IL-10 secretion by B-1 cells
via TLR-4, suppressing thereby macrophage activities. These
data emphasize the importance of S100A9 and B-1 cells to
orchestrate inflammatory response and its resolution.
5. Conclusion
The downregulatory effects of mS100A9p on macrophages
are mediated by B-1 cells, possibly via IL-10 secretion. Taken
together, our data showed that mS100A9p is a good research
tool to understand S100A9 function on the development and
maintenance of the inflammatory process and demonstrated
a pivotal role of B-1 cells mediating the action of the C-
terminus of S100A9 on control of innate immunity.
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